Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
ROCKET PHARMACEUTICALS, INC. (RCKT)
A forensic read on ROCKET PHARMACEUTICALS, INC. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Distress
Financial health
-10.2
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-70.8%
ROE
$355M
Market cap
ROCKET PHARMACEUTICALS, INC. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is -10.2, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-82%Return on invested capital.Return on invested capital is -82% and slipping from -48% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+21.0%/yrShare-count dilution.Diluted share count changed +63% over the last 3 years to FY2025 (+21.0%/yr). The count is GROWING — existing holders are being diluted. That's ~21.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~63%.
stoppedShareholder returns — halted.Capital returns have STOPPED — $72,000 of buybacks + dividends in FY2020, but ~$0 in FY2021. A halt usually means the company is conserving cash; understand why before reading it as neutral.
Key fundamentals
Free Cash Flow$-190.5M
Return on Equity-80.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on ROCKET PHARMACEUTICALS, INC.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about RCKT's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown